For the first time in the century-long history of insulin therapy, a lab-grown cell treatment has freed the majority of Type 1 diabetes patients from daily injections. Vertex Pharmaceuticals' zimislecel — stem cells engineered into insulin-producing islet cells — achieved insulin independence in 83% of trial participants, with regulatory submission to the FDA expected later this year.
What Is Zimislecel?
Zimislecel (formerly VX-880) is an investigational cell therapy developed by Vertex Pharmaceuticals in collaboration with CRISPR Therapeutics. Unlike traditional diabetes management — which relies on external insulin via injections or pumps — zimislecel replaces the destroyed beta cells that the disease wipes out.
The therapy works by infusing lab-grown, stem cell-derived islet cells into the patient's liver via the hepatic portal vein. Once implanted, these cells detect blood sugar levels and produce insulin on their own, effectively restoring the body's natural glucose regulation.
- Zimislecel restores natural insulin production using lab-grown stem cells
- Patients still require immunosuppressant drugs to prevent rejection
- FDA filing expected in 2026; potential availability by 2027
- Initially targets ~60,000 patients with severe hypoglycemia in the US and Europe
- A next-generation gene-edited version aims to eliminate immunosuppression entirely
The Trial Results That Changed Everything
Data published in the New England Journal of Medicine in June 2025 confirmed what researchers had hoped for decades. In the Phase 1/2 FORWARD-101 trial, all 12 patients who received a full dose showed engraftment — the cells took hold and began producing insulin.
The numbers tell the story:
| Metric | Result |
|---|---|
| Insulin independence at 12 months | 10 of 12 patients (83%) |
| HbA1c below 7.0% (ADA target) | 12 of 12 (100%) |
| Time-in-range above 70% | 12 of 12 (100%) |
| Severe hypoglycemic events post-day 90 | Zero |
| Mean insulin reduction (all patients) | 92% |
Dr. Michael Rickels, the lead investigator at the University of Pennsylvania, called the data "remarkable," noting the elimination of severe hypoglycemic events — the life-threatening blood sugar crashes that make severe T1D so dangerous.
From Harvard Lab to FDA Filing: The Timeline
The path to zimislecel spans over a decade of scientific breakthroughs, corporate acquisitions, and one devastating setback.
The story of Brian Shelton deserves special mention. As the first person to receive VX-880 in 2021, he became "Patient Zero" of the diabetes cure era — achieving insulin independence after living with T1D for decades. Shelton passed away in 2024 from causes unrelated to the trial, but his contribution to medical history is permanent.
The $1.37 Billion Bet
Vertex has invested aggressively to own this space. The financial commitment reveals how confident the company is in the science.
KEY STAT: The global Type 1 diabetes market is projected to reach $17.5 billion by 2033 — and zimislecel could capture a significant share if approved.
The initial target population is relatively narrow: approximately 60,000 patients in the US and Europe with the most severe form of T1D, characterized by impaired hypoglycemic awareness and recurrent severe episodes. But the long-term vision is far broader.
The Catch: Immunosuppression
Zimislecel is not yet a perfect cure. Patients must take chronic immunosuppressant drugs — the same class of medications used after organ transplants — to prevent their immune systems from destroying the new cells. These drugs carry real risks.
- Eliminates need for daily insulin injections
- Restores natural blood sugar regulation
- Removes risk of severe hypoglycemic episodes
- First functional cure in 100 years of T1D treatment
- Requires lifelong immunosuppression
- Immunosuppressants increase infection and kidney strain risk
- Currently limited to most severe T1D cases
- Long-term durability beyond 2 years still being studied
- Expected to be extremely expensive at launch
This is exactly why the next phase of research matters so much.
The Next Frontier: Gene-Edited Cells That Hide From the Immune System
Vertex and CRISPR Therapeutics are developing a "hypoimmune" version of the therapy using CRISPR-Cas9 gene editing. The idea: modify the stem cells before transplant so they are invisible to the patient's immune system, eliminating the need for immunosuppressants entirely.
They're not alone. Sana Biotechnology has already shown early results with gene-edited islet cells in a patient in Sweden who began producing insulin without anti-rejection drugs. CRISPR Therapeutics is running its own trial with CTX211, an immune-evasive beta cell therapy. And researchers at the Medical University of South Carolina are developing a dual approach combining lab-grown cells with engineered immune cells for protection.
What Didn't Work
Not every approach has succeeded. Vertex's VX-264 — which encapsulated islet cells inside a protective device to avoid immunosuppression — was discontinued in March 2025. The encapsulation concept was elegant: a physical barrier that lets insulin out while keeping immune cells away. In practice, the body built scar tissue around the device, starving the cells of oxygen and preventing adequate insulin production.
What Happens Next
Vertex is currently running a Phase 3 pivotal trial with 50 participants. If the data holds, the company plans to file for FDA approval in late 2026. Zimislecel already holds a Regenerative Medicine Advanced Therapy (RMAT) designation, which could fast-track regulatory review.
If approved under priority review, the therapy could reach patients as early as 2027. Meanwhile, the gene-editing pipeline — the key to unlocking this treatment for all T1D patients — continues advancing in parallel. Vertex has broken ground on a dedicated manufacturing facility in Portsmouth, New Hampshire, to produce these cells at commercial scale.
For the 1.5 million Americans living with Type 1 diabetes, and the millions more worldwide, the question is no longer if a functional cure is possible. It's when — and for whom.
